1-6 of 6
L. Austin Doyle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M. Greer, L. Austin Doyle, John J. Wright, Judith E. Karp, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3592–3600.
https://doi.org/10.1158/1078-0432.CCR-16-2629
Published: 13 July 2017
View articletitled, Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Open the PDF for Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda Weigel, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1558–1565.
https://doi.org/10.1158/1078-0432.CCR-14-0595
Published: 31 March 2015
View articletitled, A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View articletitled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Marina Y. Konopleva, Roland B. Walter, Stefan H. Faderl, Elias J. Jabbour, Zhihong Zeng, Gautam Borthakur, Xuelin Huang, Tapan M. Kadia, Peter P. Ruvolo, Jennie B. Feliu, Hongbo Lu, LaKiesha Debose, Jan A. Burger, Michael Andreeff, Wenbin Liu, Keith A. Baggerly, Steven M. Kornblau, L. Austin Doyle, Elihu H. Estey, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-13-1978
Published: 15 April 2014
View articletitled, Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Open the PDF for Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark H. Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poire, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab L. Atallah, Philip Dy, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 490–498.
https://doi.org/10.1158/1078-0432.CCR-13-1311
Published: 16 January 2014
View articletitled, Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Open the PDF for Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial in another window
Includes: Supplementary data
Journal Articles

Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients

Takeo Nakanishi, Judith E. Karp, Ming Tan, L. Austin Doyle, Todd Peters, Weidong Yang, David Wei, Douglas D. Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3320–3328.
Published: 05 September 2003
View articletitled, Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients
Open the PDF for Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients in another window